{"id":637855,"date":"2023-02-10T19:58:01","date_gmt":"2023-02-10T19:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=637855"},"modified":"2023-02-10T19:58:01","modified_gmt":"2023-02-10T19:58:01","slug":"the-acute-on-chronic-liver-failure-market-to-grow-positively-at-a-significant-cagr-during-the-study-period-20192032-assesses-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-acute-on-chronic-liver-failure-market-to-grow-positively-at-a-significant-cagr-during-the-study-period-20192032-assesses-delveinsight_637855.html","title":{"rendered":"The Acute on Chronic Liver Failure Market to Grow Positively at a significant CAGR During the Study Period (2019-2032), Assesses DelveInsight"},"content":{"rendered":"
\"The<\/a><\/div>\n

DelveInsight’s “Acute on Chronic Liver Failure Market Insight, Epidemiology and Market Forecast 2032<\/a>”<\/strong> report provides current treatment practices, emerging drugs, Acute On Chronic Liver Failure market share of the individual therapies, current and forecasted Acute On Chronic Liver Failure market size from 2019 to 2032 segmented by seven major markets. The report also offers current Acute On Chronic Liver Failure therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute On Chronic Liver Failure market.<\/p>\n

 <\/p>\n

Acute On Chronic Liver Failure Overview<\/strong><\/p>\n

The term ‘acute-on-chronic liver failure’ (ACLF) defines an abrupt and life-threatening worsening of clinical conditions in patients with cirrhosis or chronic liver disease. ACLF is a serious condition with very high morbidity and mortality.  According to European Association for the Study of the Liver – Chronic Liver Failure (EASL-CLIF) Consortium the definition of ACLF is based on the existence of the failure of 1 of the 6 major organ systems. The failure of each organ system is assessed using the CLIF-C Organ Failure scale<\/p>\n

According to NACSELD, the most prevalent organ system failures were brain (36%)<\/strong>, followed by circulatory (16%)<\/strong>, kidney (13%)<\/strong>, and respiratory (9%)<\/strong>.3 The observed 30-day mortality rate progressively increased from 4% in patients without any OF, to 27%,<\/strong> 49%,<\/strong> 64%<\/strong> and 77%<\/strong> in patients with 1, 2, 3, or 4<\/strong> OFs, respectively.<\/p>\n

The most frequent precipitating disorders for acutely decompensated cirrhosis, with or without ACLF, were both hepatic (alcohol-induced liver injury) and extrahepatic (bacterial infections or gastrointestinal haemorrhage).<\/p>\n

 <\/p>\n

Acute On Chronic Liver Failure Epidemiological Insights<\/strong><\/p>\n

According to Delveinsight, grade 1 cases accounted for maximum number of acute on chronic liver failure cases. <\/p>\n

 <\/p>\n

Acute On Chronic Liver Failure Treatment Market<\/a> <\/strong><\/p>\n

At present, there is no specific treatment accessible for patients with ACLF. The management of ACLF includes etiology-based treatment, controlling and treating complications, providing artificial liver support system, and liver transplantation. Admission of patients with ACLF should be considered preferably in transplant centers. Organ functions need to be monitored closely and organ-specific treatment is required to restrict the development of multiorgan failures. <\/p>\n

The main principles of management in these patients are to provide support to each of the organs with failure and to promote recovery of the hepatic gland. The current treatment includes the use of devices for detoxification, antiviral therapy, and liver transplantation.<\/p>\n

 <\/p>\n

Promising Therapiesin the Acute On Chronic Liver Failure Pipeline<\/a><\/strong><\/p>\n